PFE
Pfizer Inc. · Healthcare
27.83
1.73%(-0.49)
Prev. Close27.89
0.22%(+0.06)
Pre-marketLast Updated: — ET
52W L: $20.9252W H: $28.75
$27.84
CHG+1.23 (+4.62%)
H$28.74
L$26.35
VOL598M
PFE (1h)
Pfizer Inc. · Healthcare
Pharmaceutical companies AbbVie (NYSE:ABBV | ABBV Price Prediction) and Pfizer (NYSE:PFE) both reported fourth-quarter earnings in early February, revealing two very different pharmaceutical stories.
Leo Wealth LLC grew its holdings in shares of Pfizer Inc. (NYSE: PFE) by 25.4% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 135,861 shares of the biopharmaceutical company's stock after acquiring an additional 27,559 shares during the quarter. Leo Wealth LLC's
Stratos Wealth Partners LTD. reduced its holdings in shares of Pfizer Inc. (NYSE: PFE) by 14.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 213,361 shares of the biopharmaceutical company's stock after selling 35,463 shares during the quarter. Stratos
Capricorn Fund Managers Ltd bought a new stake in Pfizer Inc. (NYSE: PFE) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 165,569 shares of the biopharmaceutical company's stock, valued at approximately $4,123,000. A number of
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.26%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.
Aberdeen Group plc lessened its position in Pfizer Inc. (NYSE: PFE) by 11.3% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,205,453 shares of the biopharmaceutical company's stock after selling 664,801 shares during the period. Aberdeen Group plc owned approximately 0.09% of
BOURLA ALBERT
director, officer: Chairman & CEO
21 SH @ $0.00
2026-03-31
Taraporevala Cyrus
director
1,386.834 SH @ $0.00
2026-03-27
SMITH JAMES C
director
1,664.201 SH @ $0.00
2026-03-27
Quincey James
director
1,433.062 SH @ $0.00
2026-03-27
NARAYEN SHANTANU
director
1,849.112 SH @ $0.00
2026-03-27
Echevarria Joseph
director
1,710.429 SH @ $0.00
2026-03-27
Buckley Mortimer J
director
1,386.834 SH @ $0.00
2026-03-27
BOURLA ALBERT
director, officer: Chairman & CEO
1,630 SH @ $0.00
2026-03-13